4D Molecular Therapeutics, Inc. Common Stock (FDMT) is a publicly traded Healthcare sector company. As of July 15, 2026, FDMT trades at $11.35 with a market cap of $590.72M and a P/E ratio of -4.56. FDMT moved +3.45% today. Year to date, FDMT is +56.00%; over the trailing twelve months it is +167.12%. Its 52-week range spans $2.24 to $14.00. Analyst consensus is strong buy with an average price target of $30.33. Rallies surfaces FDMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for FDMT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $11.35 |
| Market Cap | $590.72M |
| P/E Ratio | -4.56 |
| EPS | $-2.57 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.00 |
| 52-Week Low | $2.24 |
| Volume | 520.22K |
| Avg Volume | 0 |
| Revenue (TTM) | $88.24M |
| Net Income | $-160.90M |
| Gross Margin | 0.00% |
7 analysts cover FDMT: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.33.